Drug utilization review (DUR) is defined as an authorized, structured, ongoing review of prescribing, dispensing and use of medication. DUR encompasses a drug review against predetermined criteria that results in changes to drug therapy when these criteria are not met.
Medication errors are among the most common medical errors, harming at least 1.5 million people every year. The extra medical costs of treating drug-related injuries occurring in hospitals alone are at least to $3.5 billion a year, and this estimate does not take into account lost wages and productivity or additional health care costs.
Disease management is the concept of reducing health care costs and improving quality of life for individuals with chronic conditions by preventing or minimizing the effects of the disease through integrated care. Disease management programs are designed to improve the health of persons with chronic conditions and reduce associated costs from avoidable complications by identifying and treating chronic conditions more quickly and more effectively, thus slowing the progression of those diseases.
AMCP Format 4.1 includes new sections describing the evidence needs of HCDMs for unapproved products nearing the end of the product development pipeline, as well as unapproved uses of existing products for which FDA approval is being sought.
Partnership Forum: Now more than ever, there is an increased focus on health disparities that occur across a multitude of factors, including socioeconomic status, ethnicity, and race. This forum helped identify potential structural issues within the current formulary and benefit design processes that may have led to racial health disparities or inequality.
Where We Stand: AMCP supports the use of MAC pricing as a managed care tool to encourage the dispensing of cost saving generic drugs and thereby benefiting the overall health care system.
AMCP submitted a letter on the reopened comment period for the Medicaid Coverage of Innovative Technologies rule, which created a pathway for fast national Medicare coverage of innovative technologies, including digital therapeutics.
